Weight-loss drugs linked to rise in diagnoses

GLP-1 prescriptions helping people who previously avoided doctors.

Sign up for Reuters newsletters One Essential Read One Essential Read Recommended by Kate Turton, Newsletter Editor Weight-loss drugs draw Americans back to the doctor   Some people who had avoided doctors because of stigma of obesity are accessing long-delayed preventative care. Mark Black/UChicago Medicine/Handout via REUTERS An exclusive analysis of hundreds of thousands of electronic patient records has found increases in first-time diagnoses of sleep apnea, cardiovascular disease and type 2 diabetes within 15 days of an initial prescription for a GLP-1 weight-loss drug between 2020 and 2024. These powerful weight-loss drugs are expanding use of US health care as patients starting prescriptions are diagnosed with obesity-related conditions or take the drugs to become eligible for other services, health records and discussions with doctors show. Read the full article Sponsors are not involved in the creation of newsletters or other Reuters news content. Advertise in this newsletter or on Reuters.com Reuters One Essential Read is sent three days a week. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here. Want to stop receiving this email? Unsubscribe here. To manage which newsletters you're signed up for, click here. Terms & Conditions and Privacy Statement © 2024 Thomson Reuters. All rights reserved. 3 Times Square, New York, NY 10036